Thomas Dittrich is the latest “boomerang” executive to return to a former employer as CFO. Over a decade ago he was the ...

The Japanese drugmaker that sells rare-disease medicine Tavneos said new patients will be able to get the drug, which carries ...

Amgen (AMGN) stock is in focus after safety concerns around its rare disease therapy Tavneos, including reported patient ...

After some six years at the post, Amgen’s finance chief is telegraphing his exit from the California pharma by early next ...

After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once ...

May 19 (Reuters) - Amgen said on Tuesday its chief financial officer, Peter Griffith, would retire, with Thomas Dittrich ...

Amgen named Thomas Dittrich, a former finance executive at the company, as its next chief financial officer. The biotechnology company said Tuesday that Dittrich will succeed Peter Griffith, who is ...

Kissei Pharmaceutical has revised a package insert in Japan for Amgen's rare immune-disease drug Tavneos, saying that serious liver dysfunction could occur. The Japanese pharmaceutical company said ...

Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new ...

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and ...

Cosette Pharmaceuticals named David Bell as chief commercial officer of brands. Heidi Health appointed Jessie Young as ...